Mordente A., et al. Free radical production by activated haem proteins: protective effect of coenzyme Q. Molec Aspects Med. 1994; 15(Suppl S109–S115).
Murphy A. N., Fiskum G., Beal F. Mitochondria in neurodegeneration: bioenergetic function in cell life and death. J Cereb Blood Flow Metab. 1999; 19(№ 3):231–45.
Musumeci O., et al. Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. Neurology. 2001 Apr 10; 56(7):849–55.
Nam M. K., et al. Essential roles of mitochondrial depolarization in neuron loss through microglial activation and attraction toward neurons. Brain Res. 2013 Apr 10; 1505:75–85. Epub Feb 12. doi:10.1016/j. brainres.2013.02.005.
Novelli A., et al. Glutamate becomes neurotoxic via the N-methyl-Daspartate receptor when intracellular energy levels are reduced. Brain Res.1988 Jun 7; 451(1–2):205–12. doi:10.1016/0006-8993(88)90765-2. Ristow M., et al. Frataxin activates mitochondrial energy conversion and oxidative phosphorylation. Proc Natl Acad Sci U S A. 2000; 97(№ 22):12239–43. doi:10.1073 /pnas.220403797.
Schon E. A., Manfredi G. Neuronal degeneration and mitochondrial dysfunction. J Clin Invest. 2003 Feb; 111(3):303–12. doi:10.1172/JCI17741. Schulte E. C., et al. Mitochondrial membrane protein associated neurodegenration: A novel variant of neurodegeneration with brain iron accumulation. Mov Disord. 2013 Feb; 28(2):224–7. Epub 2012 Nov 19. doi:10.1002/mds.25256.
Schulz J. B., et al. Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases. Neuroscience 71. 1996; 71(4):1043–48. doi:10.1016/0306-4522(95)00527-7.
Sobreira C, et al. Mitochondrial encephalomyopathy with coenzyme Q10 deficiency. Neurology. 1997 May; 48(5):1238–43.
Sun T., et al. Motile axonal mitochondria contribute to the variability of presynaptic strength. Cell Rep. 2013 Aug 15; 4(3):413–9. Epub 2013 Jul 23. doi:10.1016/j.celrep.2013.06.040.
Tatton W. G., Chalmers-Redman R. M. Mitochondria in neurodegenerative apoptosis: an opportunity for therapy? Ann Neurol. 1998; 44(3 Suppl 1):S. 134–S. 141. doi:10.1002/ana.410440720.
Tatton W. G, Olanow C. W. Apoptosis in neurodegenerative diseases: the role of mitochondria. Biochim Biophys Acta. 1999 Feb 9; 1410(2):195–213. doi:10.1016/S0005-2728(98)00167-4.
Turner C., Schapira A. H. Mitochondrial dysfunction in neurodegenerative disorders and ageing. Adv Exp Med Biol. 2001; 487:229–51.
Veitch K. et al. Global ischemia induces a biphasic response of the mitochondrial respiratory chain. Anoxic pre-perfusion protects against ischaemic damage. Biochem J. 1992 Feb 1; 281(Pt 3):709–15.
Volpe M., Cosentino F. Abnormalities of endothelial function in the pathogenesis of stroke: the importance of endothelin. J Cardiovasc Pharmacol. 2000; 35(4 Suppl 2):S. 45–S. 48.
Болезнь Альцгеймера: не забывайте о митохондриях!
Berger A. The Alzheimer’s antidote: Using a low-carb, high-fat diet to fight Alzheimer’s disease, memory loss, and cognitive decline. White River Junction, VT: Chelsea Green Publishing, 2017.
Blass J. P. The mitochondrial spiral. An adequate cause of dementia in the Alzheimer’s syndrome. Ann NY Acad Sci. 2000; 924:170–83. doi:10.1111/j.1749–6632.2000.tb05576.x.
Bonilla E., et al. Mitochondrial involvement in Alzheimer’s disease. Biochim Biophys Acta. 1999 Feb 9; 1410(2):171–82. doi:10.1016/S0005-2728(98)00165-0.
Brown A. M., et al. Correlation of the clinical severity of Alzheimer’s disease with an aberration in mitochondrial DNA (mtDNA). J Mol Neurosci. 2001 Feb; 16(1):41–8. doi:10.1385 /JMN:16:1:41.
Cavallucci V., Ferraina C., D’Amelio M. Key role of mitochondria in Alzheimer’s disease synaptic dysfunction. Curr Pharm Des. 2013; 19(36):6440–50. Epub 2013 Feb 13.
Chen J. X., Yan S. D. Amyloid-beta-induced mitochondrial dysfunction. J Alzheimers Dis. 2007 Sep; 12(2):177–84. doi:10.3233/JAD-2007-12208.
Duboff B., Feany M., Götz J. Why size matters — balancing mitochondrial dynamics in Alzheimer’s disease. Trends Neurosci. 2013 Jun; 36(6):325–35. Epub 2013 Apr 11. doi:10.1016 /j.tins.2013.03.002.
Gabuzda D., et al. Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J Biol Chem. 1994 May 6; 269(18):13623–8.
Harman D. A hypothesis on the pathogenesis of Alzheimer’s disease. Ann NY Acad Sci. 1996 Jun 15;786:152–68. doi:10.1111/j.1749–6632.1996. tb39059.x.
Hu H., et al. A mitocentric view of Alzheimer’s disease. Mol Neurobiol. 2016 Oct 1. Epub ahead of print. doi:10.1007/s12035-016-0117-7.
Lustbader J. W., et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer’s disease. Science. 2004 Apr 16; 304(5669):448–52. doi:10.1126/science.1091230.
Mariani C., et al. Muscle biopsy in Alzheimer’s disease: morphological and biochemical findings. Clin Neuropathol. 1991 Jul; 10(4):171–6.
Mark R. J., et al. Amyloid b-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J Neurosci. 1997 Feb 1; 17(3): 1046–54.
Markesbery W. R. Oxidative stress hypothesis in Alzheimer’s disease. Free Radic Biol Med. 1997; 23(1):134–47. doi:10.1016/S0891-5849(96)00629-6. Markesbery W. R. Oxidative alterations in Alzheimer’s disease. Brain Pathol. 1999 Jan; 9(1): 133–46. doi:10.1111/j.1750–3639.1999.tb00215.x. Muller W. E., et al. Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer’s disease-therapeutic aspects. Mol Neurobiol. 2010 Jun; 41(2–3):159–71. doi:10.1007/s12035-010-8141-5.
Munch G., et al. Alzheimer’s disease — synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm (Vienna). 1998; 105(4–5):439–61. doi:10.1007/s007020050069.
Nia S. S., et al. New pathogenic variations of mitochondrial DNA in Alzheimer disease! [letter]. J Res Med Sci. 2013 Mar; 18(3):269.
Nicotera P., Leist M., Manzo L. Neuronal cell death: a demise with different shapes. Trends Pharmacol Sci. 1999 Feb 1; 20(2):46–51. doi:10.1016/ S0165-6147(99)01304-8.
Ogawa M, et al. Altered energy metabolism in Alzheimer’s disease. J Neurol Sci. 1996 Jul; 139(1):78–82. doi:10.1016/0022-510X(96)00033-0.
Sery O., et al. Molecular mechanisms of neuropathological changes in Alzheimer’s disease: a review. Folia Neuropathol. 2013; 51(1):1–9. doi:10.5114/fn.2013.34190.
Smith M. A., et al. Widespread peroxynitrite-mediated damage in Alzheimer’s disease. J Neurosci 1997 Apr 15; 17(8):2653–7.
